United Therapeutics
UTHR
535 hedge funds and large institutions have $9.95B invested in United Therapeutics in 2023 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 201 increasing their positions, 170 reducing their positions, and 41 closing their positions.
90% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 41
18% more repeat investments, than reductions
Existing positions increased: 201 | Existing positions reduced: 170
5% more funds holding
Funds holding: 508 → 535 (+27)
1.34% more ownership
Funds ownership: 94.78% → 96.12% (+1.3%)
1% less capital invested
Capital invested by funds: $10.1B → $9.95B (-$111M)
27% less call options, than puts
Call options by funds: $24.8M | Put options by funds: $33.9M
44% less funds holding in top 10
Funds holding in top 10: 18 → 10 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$130M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$110M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$54.7M |
| 4 |
BlackRock
New York
|
+$42.3M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$75.6M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$69.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$65.4M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$47.6M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$41.5M |
UTHR Hedge Fund Activity: Q4 2023 in Review
535 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2023, worth a combined $9.95B — down 1.1% from $10.1B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new UTHR positions and 41 closed out — a net gain of 37 holders — while 201 added to existing stakes and 170 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $130M. The largest seller was Wellington Management Group, cutting an estimated $75.6M.
- 535 institutional investors held United Therapeutics (UTHR) as of Q4 2023, up from 508 in Q3 2023.
- Funds reported $9.95B of United Therapeutics stock for Q4 2023, down 1.1% quarter-over-quarter.
- 78 funds opened new United Therapeutics positions in Q4 2023 and 41 closed out, a net change of +37 holders.
- The largest United Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $130M added.
- The largest United Therapeutics seller in Q4 2023 was Wellington Management Group, an estimated $75.6M sold.
Based on aggregated 13F filings for Q4 2023.